ChiCTR2000038661 版本V1.7 版本创建时间2020/11/19 10:44:09 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038661 

最近更新日期:

Date of Last Refreshed on:

2020-11-19 10:42:52 

注册时间:

Date of Registration:

2020-09-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

结直肠癌术后肠动力恢复评估模型的构建及应用效能的研究

Public title:

Development and validation intelligence assessment models for intestinal motility recovery after colorectal cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

结直肠癌术后肠动力恢复评估模型的构建及应用效能的研究

Scientific title:

Development and validation intelligence assessment models for intestinal motility recovery after colorectal cancer surgery

研究课题代号(代码):

Study subject ID:

No.2019YFS0387

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谢恬 

研究负责人:

杨慧 

Applicant:

Tian Xie 

Study leader:

Hui Yang 

申请注册联系人电话:

Applicant telephone:

+86 18483696250

研究负责人电话:

Study leader's telephone:

+86 18908191080

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

786341834@qq.com

研究负责人电子邮件:

Study leader's E-mail:

910638755@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市人民南路四段55号

研究负责人通讯地址:

四川省成都市人民南路四段55号

Applicant address:

55 Fourth Section of Renmin Road South, Chengdu, Sichuan, China

Study leader's address:

55 Fourth Section of Renmin Road South, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川省肿瘤医院

Applicant's institution:

Sichuan Cancer Hospital

研究负责人所在单位:

四川省肿瘤医院

Affiliation of the Leader:

Sichuan Cancer Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SCCHEC-02-2020-059

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川省肿瘤医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Sichuan Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-11-10 00:00:00

伦理委员会联系人:

周维佳

Contact Name of the ethic committee:

Weijia Zhou

伦理委员会联系地址:

四川省成都市人民南路四段55号

Contact Address of the ethic committee:

55 Fourth Section of Renmin Road South, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川省肿瘤医院

Primary sponsor:

Sichuan Cancer Hospital

研究实施负责(组长)单位地址:

四川省成都市人民南路四段55号

Primary sponsor's address:

55 Fourth Section of Renmin Road South, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川省肿瘤医院

具体地址:

人民南路四段55号

Institution
hospital:

Sichuan Cancer Hospital

Address:

55 Fourth Section of Renmin Road South

经费或物资来源:

四川省科技厅课题

Source(s) of funding:

Sichuan Province Science and Technology Support Program(No.2019YFS0387)

Target disease:

Colorectal Cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

分析结直肠癌术后肠动力恢复的临床特点,识别结直肠癌术后肠动力恢复的危险因素和促进因素,构建结直肠癌术后肠动力恢复的评估模型并验证其效能,从而开发结直肠癌术后肠动力恢复的评估模型软件以便于临床早期发现,超前干预。  

Objectives of Study:

To analyze the clinical characteristics and the risk factors and promoting factors of intestinal motility recovery after colorectal cancer surgery, and develop an evaluation model of colorectal motility recovery after colorectal cancer surgery and validate it, so as to develop an evaluation model software for colorectal motility recovery after colorectal cancer surgery for clinical early detection and intervention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 2020年11月-2021年6月住院患者;
(2) 病理诊断为结直肠癌;
(3) 年龄在18-90岁;
(4) 住院期间接受手术治疗;
(5) 自愿参加研究并已签署知情同意书;
(6) 具有正常的语言表达能力。

Inclusion criteria

(1) Inpatients from November 2020 to June 2021;
(2) The pathological diagnosis was colorectal cancer;
(3) Aged between 18 and 90 years;
(4) Receive surgical treatment during hospitalization;
(5) Voluntary participation in the study and signed informed consent;
(6) Normal language ability.

排除标准:

(1) 术前有下肢功能障碍;
(2) 术前有进食吞咽困难;
(3) 术后72小时以内死亡或者出院、转院。

Exclusion criteria:

(1) Preoperative lower limb dysfunction;
(2) Preoperative difficulty in eating and swallowing;
(3) Death or discharge or transfer within 72 hours after surgery.

研究实施时间:

Study execute time:

From 2020-10-26 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-26 00:00:00 To 2021-06-30 00:00:00  

干预措施:

Interventions:

组别:

病例vs对照组

样本量:

478

Group:

Case group vs control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

排便

指标类型:

主要指标

Outcome:

defecation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

排气

指标类型:

主要指标

Outcome:

fart

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

主要指标

Outcome:

Time of hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院费用

指标类型:

主要指标

Outcome:

hospitalization costs

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

REDCap http://125.71.214.100:888/redcap/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

REDCap http://125.71.214.100:888/redcap/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例观察报告表和REDCap

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Report Form and REDCap

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-09-27 20:48:50